Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 18/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20985774 | 0.85 | ROCK2 (1.00) | ROCK2ROCK1TP53RXFP1 | |
| SCHEMBL19643877 | 0.83 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL19643514 | 0.79 | ROCK2 (0.83) | ROCK2ROCK1 | |
| SCHEMBL17912995 | 0.79 | ROCK2 (0.65) | ROCK2ROCK1 | |
| SCHEMBL22943962 | 0.78 | ROCK1 (0.67) | ROCK2ROCK1 | |
| SCHEMBL19643886 | 0.77 | ROCK2 (0.76) | ROCK2ROCK1 | |
| SCHEMBL20985775 | 0.76 | ROCK2 (0.61) | ROCK2ROCK1ADORA2A | |
| SCHEMBL19643936 | 0.75 | ROCK2 (1.00) | ROCK2ROCK1TP53RXFP1 | |
| SCHEMBL21405570 | 0.74 | ROCK2 (0.75) | ROCK2ROCK1TP53RXFP1 | |
| SCHEMBL22952635 | 0.74 | ROCK1 (0.68) | ROCK2ROCK1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464262-B1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | claimed |
| US-10562887-B2 | Triazolones and tetrazolones as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-18 | — | — | US | claimed |
| EP-3464262-B1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3464262-B1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10562887-B2 | Triazolones and tetrazolones as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562887-B2 | Triazolones and tetrazolones as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190152956-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190152956-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3464262-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017205709-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152956-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | MYLK, ROCK1, MYLK2 | ROCK2 5/4885ROCK1 2/4885TP53 2634/4885 |
| US-10562887-B2 | Triazolones and tetrazolones as inhibitors of ROCK | MYLK, ROCK1, MYLK2 | ROCK2 5/4885ROCK1 2/4885TP53 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.